In FAERS reports, dulaglutide was associated with greater reporting of gastrointestinal adverse reactions than other approved drugs in its class.
In plain wordsIn safety reports, dulaglutide was linked to more gastrointestinal reaction reports than other drugs in its class.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- IncreaseGastrointestinal adverse reaction reporting
- Study
n: not reported in source
- Comparator
- Other approved drugs in the therapeutic class
- Outcome group
- Gastrointestinal adverse events · Gastrointestinal
- Studied dose
- Dose not stated
Source sentences
Assessing glucagon-like peptide-1 (GLP-1) receptor agonists, dulaglutide and semaglutide were associated with greater reports of gastrointestinal adverse drug reactions.
2 context sentences(design, population, supporting numbers)
A disproportionality analysis of spontaneously reported ADRs was conducted.
Reporting odds ratios were calculated for the top 10 ADRs, comparing new diabetic agents to the other approved drugs in their therapeutic class.